Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Developed by researchers at Tongji Medical College, Huazhong University of Science and Technology, this radiotracer is designed for the non-invasive visualization of total tumor EGFR expression and distribution [EP-0032].
| Indication | Highest phase | Status |
|---|---|---|
| non-small-cell lung cancer (NSCLC) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: non-small-cell lung cancer (NSCLC)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]-Compound 9.
Work on [18F]-Compound 9? Claim this page to correct or add information. Claim this page